Evidence map›Paper›PMID 41665963›Full record

ArticleJCI insight2026

Epidermal NAD+ deficiency induces IL-36-mediated skin inflammation and acanthosis.

Taiki Seki, Jun-Dal Kim, Yasuhito Yahara, Hitoshi Uchida, Keisuke Yaku, Mariam Karim, Teruhiko Makino, Tadamichi Shimizu, Takashi Nakagawa

Abstract read
In one paragraph

Article in JCI insight, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Taiki SekiDepartment of Molecular and Medical Pharmacology, Faculty of Medicine.
Jun-Dal KimDivision of Complex Biosystem Research, Department of Research and Development, Institute of Natural Medicine, University of Toyama, Toyama, Japan.
Yasuhito YaharaDepartment of Molecular and Medical Pharmacology, Faculty of Medicine.
Hitoshi UchidaDepartment of Molecular and Medical Pharmacology, Faculty of Medicine.
Keisuke YakuDepartment of Molecular and Medical Pharmacology, Faculty of Medicine.
Mariam KarimDepartment of Molecular and Medical Pharmacology, Faculty of Medicine.
Teruhiko MakinoDepartment of Dermatology, Faculty of Medicine, and.
Tadamichi ShimizuDepartment of Dermatology, Faculty of Medicine, and.
Takashi NakagawaDepartment of Molecular and Medical Pharmacology, Faculty of Medicine.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Nicotinamide adenine dinucleotide (NAD+) is essential for cellular metabolism, DNA repair, and stress responses. NAD+ is synthesized from nicotinamide, nicotinic acid (collectively termed niacin), and tryptophan. In humans, deficiencies in these nutrients result in pellagra, marked by dermatitis, diarrhea, and dementia. The dermatitis associated with pellagra typically manifests as photodermatosis in sun-exposed areas. This study examined the effects of NAD+ deficiency on skin homeostasis using epidermis-specific Nampt-conditional KO (Nampt-cKO) mice. These mice displayed substantial NAD+ depletion, reduced poly(ADP-ribose) polymerase (PARP) activity, and increased DNA damage. Consequently, Nampt-cKO mice developed spontaneous skin inflammation and epidermal hyperplasia. RNA-seq and IHC analyses demonstrated increased IL-36 cytokine expression, suggesting that DNA repair-related genomic stress triggers keratinocyte-driven IL-36 production, which promotes inflammation. Furthermore, reduced COL17A1 expression and elevated thymic stromal lymphopoietin (TSLP) levels were observed. NAD+ repletion by transdermal supplementation of nicotinamide mononucleotide (NMN) suppressed the rise of IL-36 levels and skin inflammation. These findings underscore the importance of Nampt-mediated NAD+ metabolism for epidermal stability and indicate that NAD+ depletion may contribute to IL-36-mediated skin inflammation, offering insights for therapeutic strategies in inflammatory skin disorders.

Indexed as

DermatitisEpidermisInterleukin-1NADPellagraAnimalsCytokinesDisease Models, AnimalDNA DamageDNA RepairHumansInflammationKeratinocytesMiceMice, KnockoutNicotinamide PhosphoribosyltransferaseCytokinesInterleukin-1NADNicotinamide Phosphoribosyltransferasenicotinamide phosphoribosyltransferase, mouseCytokinesDermatologyDNA repairMetabolism

Identifiers

PMID41665963
PMCPMC13043086

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.